Key Takeaways
- Volume-led growth, margin expansion: Sales grew on strong volumes and new launches, while backward integration and cost focus drove a significant improvement in operating profit margins.
- Ibuprofen is the near-term engine: With US and Europe approvals in hand and commercial supplies underway, Ibuprofen is on an upward trajectory and is expected to be the biggest growth driver.
- Price erosion is a persistent drag: Volume growth of 15-20% in top products is being partially offset by price pressure, sometimes reaching 20%, as the company fights to retain business.
- Fundraise signals capacity build: A Rs. 114.3 crore warrant issue to promoters, with 55% earmarked for CAPEX, confirms management is betting on volume expansion despite a volatile pricing environment.
- What to watch next quarter: The pace of Ibuprofen customer additions in regulated markets, any stabilization in the industry-wide price erosion flagged for the next 6-9 months, and the detailed CAPEX plan disclosure.
Growth Drivers & Product Performance
- Ibuprofen ramp-up: Gained considerable traction after US and Europe approval, with commercial supplies started in several regulated countries. The company is now trying to add ROW countries and expects to sequentially add new customers and witness better volume offtake.
- ARV segment momentum: Demonstrated vital progress with an optimistic upward trend in sales, driven by B2B contract manufacturing where big customers have won good tenders this year. Management anticipates this tender-driven strength will continue.
- Sitagliptin volumes: The anti-diabetic product is experiencing a significant increase in volume, contributing to the broader therapeutic category growth.
- Niche pipeline loading: The niche product pipeline is doing relatively good, with growth set to receive additional momentum from new products scheduled for launch in FY25. The company plans to file a minimum of 10 US DMFs in the upcoming fiscal year.
Margin & Cost Strategy
- Backward integration is the primary defense: With limited control over market pricing, management is focusing the majority of its effort on backward integrating into critical KSMs for its most critical products to reduce overall cost.
- Operating leverage kicking in: A significant rise in sales volume is allowing the company to begin reaping the benefits of operating leverage, contributing to the margin improvement.
- R&D pivoted to cost reduction: More than 50% of R&D work is now focused on cost reduction, reflecting a strategic shift to protect margins in a competitive environment.
- Plant-level optimization: The company is leveraging higher volumes to negotiate better supplier pricing and implementing batch size increases and other mechanisms to optimize costs at the plant level.
Vamsi Krishna Potluri: "the only control that we currently have with us is backward integration. So, that is the reason this year, as it was explained in the call, I think majority of the focus that we are giving is backward integrating into critical, most of our KSMs for most of our critical products."
Industry & Pricing Environment
- Consolidation and volatility ahead: Management expects the next 6 to 9 months to be a consolidation mode for the industry, characterized by significant price pressure and volatility, before settling down.
- Pervasive price erosion: Price pressure exists across segments including anti-migraine, anti-inflammatory, and diabetic spaces due to competition. Erosion varies by product and can reach 20% to retain business, partially offsetting 15-20% volume gains in top products.
- Capacity utilization ceiling: API capacity utilization cannot practically exceed 80% due to changeovers, bottlenecks, and choking. CAPEX is triggered when existing capacity approaches 75-80% occupancy, with new facilities taking 6-8 months to come online including validations.
- Red Sea disruption negligible: The majority of exports are deemed exports delivered in India, and most customers take product by air, so the Red Sea situation has had a negligible impact.
Vamsi Krishna Potluri: "for the next 6 months it will be a consolidation mode. I think people, there will be a lot of price pressure and volatility will be there for the next 6 months to 9 months, post that I think it will probably settle down once the consolidation phase happens."
Capital Allocation & Capacity
- Warrant issue to fund expansion: The board approved a Rs. 114.3 crore fundraise via convertible equity warrants to the promoter group at Rs. 127 per warrant. The allocation is 55% for CAPEX, 35% for working capital, and 10% for corporate use, subject to shareholder approval.
- CAPEX rationale: The company is undertaking CAPEX expansions now to add more volume in its facilities, consistent with its policy of investing when utilization approaches 75-80%.
- Revenue contribution undisclosed: Management declined to estimate the additional revenue the CAPEX will generate, calling it too early at this point.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Mid-teens growth | FY25 |
| EBITDA margin | 18% to 20% | FY25 |
| Export growth | 10% to 15% growth rate | Going forward |
| US DMF filings | Minimum of 10 drug master files | Upcoming fiscal year |
| CAPEX plan disclosure | Detailed CAPEX plans to be shared | Near future |
| New facility timeline | 6 to 8 months including validations | From CAPEX initiation |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue growth | 9% YoY; 24% YoY for 9M FY24 |
| API segment revenue | ₹160.3 cr; 9M FY24: ₹456.1 cr |
| API share of consolidated revenue | 99.3%; 98.4% for 9M FY24 |
| EBITDA | ₹29 cr, up 57% YoY |
| PAT | ₹11.5 cr, up 205% YoY |
| FY25 revenue growth guidance | Mid-teens growth |
| FY25 EBITDA margin guidance | 18% to 20% |
| Capacity utilization | 65% to 70%, up from 50–55% in prior quarters |
| Ibuprofen capacity utilization | ~50% |
| API export share | 88% of API revenue, including deemed exports |
| API domestic share | 12% of API revenue |
| Anti-retroviral share of sales | 33% of total sales |
| Anti-inflammatory share of sales | 18% of total sales |
| Anti-diabetic share of sales | 13% of total sales |
| Anti-migraine share of sales | 13% of total sales |
| Top 5 products volume growth | 15% to 20% YoY |
| Fundraising via warrants | ₹114.3 cr, at ₹127 per warrant |
| Warrant funds allocation to CAPEX | 55% |
| Warrant funds allocation to working capital | 35% |